Alkermes, Inc.
88 Sidney Street
Cambridge,
MA 02139-4234
United States - Map
Phone: 617-494-0171
Fax: 617-494-9263
Web Site: http://www.alkermes.com
| Alkermes, Inc., an integrated biotechnology company, offers extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction, and diabetes. It primarily develops, manufactures, and commercializes VIVITROL, an extended-release Medisorb formulation of naltrexone for the treatment of alcohol dependence, as well as for the treatment of opioid dependence. The company also manufactures RISPERDAL CONSTA, a formulation of risperidone for the treatment of schizophrenia and bipolar disorder. In addition, it is developing Exenatide once weekly for the treatment of type 2 diabetes; ALKS 33, an opioid modulator, which completed phase I randomized, double-blind, and placebo-controlled study for the treatment of addiction, pain, and other nervous system disorders; ALKS 29, an oral combination therapy for the treatment of alcohol dependence; ALKS 27, an inhaled trospium product that is in a phase IIa study for the treatment of chronic obstructive pulmonary disease; and ALKS 36, a co-formulation of an opioid analgesic and RDC-1036 for the treatment of pain. Alkermes, Inc. has collaborative arrangements with Janssen Pharmaceutica, Inc.; Cilag GmbH International; Amylin Pharmaceuticals, Inc.; and Rensselaer Polytechnic Institute. The company was founded in 1987 and is headquartered in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Richard F. Pops , 47
Chairman, Chief Exec. Officer and Pres |
$
1.03M |
$
1.63M | Mr. Michael A. Wall , 80
Founder and Chairman Emeritus |
$
36.00K | N/A | Dr. Alexander Rich M.D., 84
Founder, Director and Member of Nominating & Corp. Governance Committee |
$
46.00K | N/A | Dr. Floyd E. Bloom M.D., 72
Founder, Director, Member of Audit Committee and Member of Nominating & Corp. Governance Committee |
$
49.00K | N/A | Mr. James M. Frates , 41
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer |
$
584.00K |
$
194.00K |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
